<abstract xmlns="http://www.w3.org/1999/xhtml">Background. Lung cancer is the leading cause of cancer deaths. Angiogenesis is crucial process in cancer growth and progression. This prospective study evaluated expression of two central regulatory molecules: angiogenin and vascular endothelial growth factor (VEGF) in patients with lung cancer.Patients and methods. Clinical data, blood samples and broncho-alveolar lavage (BAL) from 23 patients with primary lung carcinoma were collected. BAL fluid was taken from part of the lung with malignancy, and from corresponding healthy side of the lung. VEGF and angiogenin concentrations were analysed by an enzyme-linked immunosorbent assay. Dilution of bronchial secretions in the BAL fluid was calculated from urea concentration ratio between serum and BAL fluid.Results. We found no statistical correlation between angiogenin concentrations in serum and in bronchial secretions from both parts of the lung. VEGF concentrations were greater in bronchial secretions in the affected side of the lung than on healthy side. Both concentrations were greater than serum VEGF concentration. VEGF concentration in serum was in positive correlation with tumour size (p = 0,003) and with metastatic stage of disease (p = 0,041). There was correlation between VEGF and angiogenin concentrations in bronchial secretions from healthy side of the lung and between VEGF and angiogenin concentrations in bronchial secretions from part of the lung with malignancy.Conclusion. Angiogenin and VEGF concentrations in systemic, background and local samples of patients with lung cancer are affected by different mechanisms. Pro-angiogenic activity of lung cancer has an important influence on the levels of angiogenin and VEGF.</abstract>

Background. Lung cancer is the leading cause of cancer deaths. Angiogenesis is crucial process in cancer growth and progression. This prospective study evaluated expression of two central regulatory molecules: angiogenin and vascular endothelial growth factor (VEGF) in patients with lung cancer.Patients and methods. Clinical data, blood samples and broncho-alveolar lavage (BAL) from 23 patients with primary lung carcinoma were collected. BAL fluid was taken from part of the lung with malignancy, and from corresponding healthy side of the lung. VEGF and angiogenin concentrations were analysed by an enzyme-linked immunosorbent assay. Dilution of bronchial secretions in the BAL fluid was calculated from urea concentration ratio between serum and BAL fluid.Results. We found no statistical correlation between angiogenin concentrations in serum and in bronchial secretions from both parts of the lung. VEGF concentrations were greater in bronchial secretions in the affected side of the lung than on healthy side. Both concentrations were greater than serum VEGF concentration. VEGF concentration in serum was in positive correlation with tumour size (p = 0,003) and with metastatic stage of disease (p = 0,041). There was correlation between VEGF and angiogenin concentrations in bronchial secretions from healthy side of the lung and between VEGF and angiogenin concentrations in bronchial secretions from part of the lung with malignancy.Conclusion. Angiogenin and VEGF concentrations in systemic, background and local samples of patients with lung cancer are affected by different mechanisms. Pro-angiogenic activity of lung cancer has an important influence on the levels of angiogenin and VEGF.

Angiogenin and vascular endothelial growth factor expression in lungs of lung cancer patients

Department for Endoscopy, University Clinic Golnik, Slovenia

Department for Pulmonology, University Clinic Golnik, Slovenia

Department for Immunology, University Clinic Golnik, Slovenia

Radiology and Oncology

Background. Lung cancer is the leading cause of cancer deaths. Angiogenesis is crucial process in cancer growth and progression. This prospective study...

Angiogenin and vascular endothelial growth factor expression in lungs of lung cancer patients

Online veröffentlicht: 09. Nov. 2012

Seitenbereich: 354 - 359

Eingereicht: 20. Jan. 2012

Akzeptiert: 21. Feb. 2012

DOI: https://doi.org/10.2478/v10019-012-0031-1

Schlüsselwörter
angiogenin, BAL fluid, bronchoscopy, lung cancer, vascular endothelial growth factor

This content is open access.

Angiogenin and vascular endothelial growth factor expression in lungs of lung cancer patients

Online veröffentlicht: 09. Nov. 2012

Seitenbereich: 354 - 359

Eingereicht: 20. Jan. 2012

Akzeptiert: 21. Feb. 2012

DOI: https://doi.org/10.2478/v10019-012-0031-1

Schlüsselwörterangiogenin, BAL fluid, bronchoscopy, lung cancer, vascular endothelial growth factor

This content is open access.

Schlüsselwörter
angiogenin, BAL fluid, bronchoscopy, lung cancer, vascular endothelial growth factor